Article Text

other Versions

A Randomized, Double-Blind, Placebo-Controlled Study of Topiramate in the Treatment of Tourette Syndrome
  1. Joseph Jankovic (josephj{at}
  1. Baylor College of Medicine, United States
    1. Joohi Jimenez-Shahed (jjimenezshahed{at}
    1. Baylor College of Medicine, United States
      1. Lawrence Brown (brownla{at}
      1. U of Pennsylvania, United States


        Objective: To investigate the effects of topiramate on Tourette syndrome.

        Background: Dopamine receptor blocking drugs have been traditionally used to control tics in patients with TS, but these neuroleptics are associated with potentially limiting side effects.

        Methods: This is a randomized, double-blind, placebo-controlled, parallel group study. To be included in the study, subjects required a DSM-IV diagnosis of TS, were 7-65 years of age, had moderate to severe symptoms (Yale Global Tic Severity Scale or YGTSS >19), were markedly impaired as determined by the Clinical Global Impression (CGI) scale severity score of >4, and were taking no more than one drug each for tics or TS co-morbidities.

        Results: There were 29 patients (26 males), mean age 16.5 ± 9.89, randomized and 20 (69%) completed the double-blind phase of the study. The primary endpoint was Total Tic Score, which improved by 14.29 ± 10.47 points from baseline to visit 5 (day 70) with topiramate (mean dose 118 mg) compared to 5.00 ± 9.88 point change in the placebo group (p = 0.0259). There were statistically significant improvements also in the other components of the YGTSS as well as improvements in various secondary measures, including the CGI and premonitory urge CGI. No differences were observed in the frequency of adverse events between the two treatment groups.

        Conclusion: This double-blind, placebo-controlled trial provides evidence that topiramate may have utility in the treatment of moderately severe TS.

        Statistics from

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.